Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pactimibe in HeFH and Carotid Atherosclerosis (CAPTIVATE)
NCT00151788Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis and heterozygous familial hypercholesterolemia (HeFH) comparing Pactimibe with Placebo (2 arms). Primary endpoint: Maximum Carotid Intima-Media Thickness at 24 months. Started Feb 2004; status: terminated.
02
Drugs
pactimibe
03
Conditions
atherosclerosisheterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00151788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151788.